Role of Age and Ph Status in Blinatumomab Selection in ALL

Jonathan Webster, MD, and Nikesh Shah, MD, describe how patient age and Philadelphia chromosome (Ph) status influence the decision to incorporate blinatumomab (Blincyto) into an ALL treatment plan. They discuss how younger adults, older adults, and patients with Ph-positive or Ph-negative disease may derive different levels of benefit based on disease biology and treatment tolerance. They also outline how these factors guide personalized treatment algorithms and optimize therapeutic outcomes.